Available online on http://www.ijhacr.com

International Journal of Health Advancement and Clinical Research (tz) 2024; 2(4); 07-12

Review Article

Sustained-Release Tablets: Evaluation and Challenges in Formulation

Vikas Kumar [1], Vijay Sharma [2], N Ravindra [3], Virender Singh [4]

[1] Research Scholar, Goenka College of Pharmacy, Lachhmangarh, Sikar.
[2] Professor, Goenka College of Pharmacy, Lachhmangarh, Sikar.
[3] Principal and Professor, Goenka College of Pharmacy, Lachhmangarh, Sikar
[4] Assistant Professor, Goenka College of Pharmacy, Lachhmangarh, Sikar.

Received: 04-10-2024 / Revised: 02-11-2024 / Accepted: 03-12-2024
Corresponding author: Vikas Kumar
Conflict of interest: Nil

Abstract:

Sustained release tablets are designed to deliver drugs at a controlled rate, optimizing therapeutic efficacy while minimizing side effects. This formulation technique improves patient compliance, reduces dosing frequency, and maintains consistent plasma drug levels. Materials such as hydrophilic polymers, hydrophobic matrices, and ion-exchange resins are commonly used to achieve sustained release properties. Evaluation of sustained release tablets involves parameters like hardness, friability, weight variation, drug content uniformity, in vitro dissolution studies, and stability testing. Despite their advantages, challenges such as dose dumping, formulation complexity, and cost remain. This article explores the principles, materials, evaluation methods, challenges, and applications of sustained release tablets in the pharmaceutical industry.

Keywords: sustained release tablets, controlled drug delivery, hydrophilic polymers, in vitro evaluation, pharmaceutical applications.

Introduction

Sustained release (SR) tablets represent an innovative drug delivery system aimed at enhancing therapeutic outcomes by maintaining a controlled drug release profile over an extended period. Unlike conventional tablets, which release the active pharmaceutical ingredient (API) immediately, SR tablets are designed to provide a prolonged and steady release of the API. [1] This approach improves patient adherence by reducing the dosing frequency, minimizes peak-to-trough fluctuations in drug plasma levels, and decreases the likelihood of adverse effects associated with high drug concentrations. Over the years, advancements in pharmaceutical technology have led to the development of various SR formulations tailored to meet specific therapeutic needs. These systems leverage advanced materials and design techniques to achieve desired release profiles. This article delves into the materials, evaluation techniques, challenges, and applications of SR tablets.[2]

Materials Suitable for Sustained Release Formulation

Hydrophilic Polymers: Materials like hydroxypropyl methylcellulose (HPMC), xanthan gum, and carboxymethylcellulose (CMC) form a gel layer around the tablet upon contact with aqueous fluids, controlling drug release through diffusion and erosion mechanisms.

Hydrophobic Matrices: Waxes, ethyl

cellulose, and hydrogenated castor oil create a barrier that slows drug release through dissolution and diffusion.

Ion-Exchange Resins: These resins bind the drug and release it slowly based on the pH and ionic environment of the gastrointestinal tract. [3]

Lipid-Based Systems: Lipids such as glyceryl behenate and stearic acid can modulate drug release through matrix formation and interaction with the drug.

Coating Agents: Polymers like Eudragit and cellulose acetate phthalate are used to coat tablets, allowing for pH-dependent or time-controlled release. [4]

Evaluation of Sustained Release Tablets

1. Weight Variation

Weight variation ensures uniformity in the dosage of the active ingredient across all tablets. Tablets are randomly selected, weighed individually, and then the average weight is compared against the individual weights. A small deviation indicates good manufacturing consistency, while large variations may compromise drug release profiles and dosage accuracy.[5]

2. Hardness

The hardness of a sustained-release tablet is a measure of its mechanical strength. This parameter ensures the tablet can withstand mechanical stresses during handling, packaging, and transportation. Hardness is assessed using hardness testers, and an optimal value is necessary to maintain the integrity of the release mechanism while ensuring ease of swallowing.

3. Friability

Friability measures the tablet's resistance to chipping or breaking under mechanical stress. Tablets are subjected to rotation in a friabilator, and the weight loss is calculated. A low friability value is desirable for sustained-release tablets to maintain their physical integrity throughout the release period. [6,7]

4. Thickness

Tablet thickness is measured to ensure uniformity across batches. Variations in thickness can affect the release mechanism, as sustained-release tablets often rely on precise dimensions to control the release rate. Thickness is typically measured using calipers or similar instruments.

5. Drug Content Uniformity

Drug content uniformity ensures each tablet contains the same amount of the active ingredient within specified limits. This parameter is crucial for therapeutic consistency and is determined using chemical assays like UV spectrophotometry or high-performance liquid chromatography (HPLC).

6. Swelling Index

The swelling index evaluates the tablet's ability to swell when in contact with gastrointestinal fluids. For tablets relying on hydrophilic matrices or polymers, swelling plays a critical role in drug release. The degree of swelling is measured by comparing the tablet’s initial and hydrated weights over time. [8]

7. In-vitro Drug Release

In-vitro drug release studies simulate the conditions of the gastrointestinal tract to determine the release profile of the active ingredient. These studies use dissolution apparatus to measure drug release at specified time intervals. The results help confirm that the drug is released at the intended rate and duration.

8. Stability Studies

Stability studies assess how the tablet's properties, such as drug release profile, hardness, and drug content, change under different environmental conditions (temperature, humidity). These studies help predict the shelf life and storage requirements of the tablets. [9]

Challenges with Sustained Release Tablets

- **Complex Formulation Development**

Developing a sustained-release tablet requires a thorough understanding of the drug's physicochemical properties and pharmacokinetics. Drugs with poor solubility, short biological half-life, or high permeability may pose challenges in achieving controlled and predictable release profiles. Additionally, selecting suitable polymers, excipients, and release mechanisms can complicate formulation design.

- **Cost of Production**

Sustained-release tablets often require advanced manufacturing techniques, specialized excipients, and extended testing protocols. This increases production costs compared to conventional immediate-release tablets. Achieving cost-efficiency without compromising quality is a significant challenge for pharmaceutical companies. [10]

- **Risk of Dose Dumping**

Dose dumping occurs when the entire drug content is released rapidly instead of gradually over time. This can result from manufacturing defects, compromised tablet integrity, or interaction with alcohol (in some cases). Dose dumping poses a risk of toxicity and reduced therapeutic efficacy.

- **Limited Drug Candidates**

Not all drugs are suitable for sustained-release formulations. Drugs with very short half-lives, narrow therapeutic indices, or poor stability in gastrointestinal fluids may not perform well in sustained-release systems. Additionally, drugs requiring rapid onset of action may not benefit from prolonged release. [11]

- **Individual Variability**

The performance of sustained-release tablets can be affected by individual patient factors, such as gastrointestinal pH, motility, and enzyme activity. Variability in these physiological conditions may lead to inconsistent drug release and absorption, affecting therapeutic outcomes.

- **Regulatory Challenges**

Sustained-release formulations must meet stringent regulatory requirements, including demonstrating bioequivalence, stability, and consistent drug release profiles. These requirements often involve extensive in-vitro and in-vivo testing, making the approval process lengthy and resource-intensive.

- **Stability Issues**

Some drugs and polymers used in sustained-release tablets may be sensitive to environmental conditions such as temperature, humidity, and light. Ensuring stability over the product's shelf life requires careful selection of materials and packaging. [12,13]

- **Difficulty in Achieving Zero-Order Release**

Designing a sustained-release system with a consistent, zero-order release profile (constant drug release rate) is challenging. Most formulations achieve first-order or pseudo-zero-order release, leading to variations in drug levels over time.

- **Patient Compliance**

While sustained-release tablets aim to improve compliance by reducing dosing frequency, they often come with strict instructions regarding administration. For instance, tablets should not be chewed, crushed, or split, as this may compromise the release mechanism. Such restrictions can be inconvenient for some patients. [11,12]

- **Compatibility Issues**

Achieving compatibility between the active ingredient and the release-controlling polymers or excipients can be challenging. Incompatibilities may lead to altered drug release, reduced stability, or formulation failure.

Application of Sustained Release in Pharmaceuticals

Sustained-release (SR) formulations are widely utilized in pharmaceuticals to enhance drug therapy by providing controlled and prolonged release of active ingredients. These formulations offer numerous therapeutic and practical benefits across various medical conditions. Below are the key applications of sustained-release systems in pharmaceuticals:

- **Chronic Disease Management**

Sustained-release tablets are extensively used in managing chronic conditions that require long-term medication adherence, such as hypertension, diabetes, and epilepsy. These formulations maintain steady drug plasma levels, reducing the frequency of dosing and enhancing patient compliance.

Example: Metformin SR for type 2 diabetes ensures consistent blood sugar control with fewer doses.

- **Pain Management**

In pain management, sustained-release formulations provide continuous relief by releasing analgesics over an extended period. This reduces the need for frequent dosing and minimizes the fluctuations in pain levels. [12]

Example: Morphine SR tablets are commonly used for chronic pain management in cancer patients and other severe conditions.

- **Cardiovascular Disorders**

SR systems help maintain stable therapeutic levels of cardiovascular drugs, reducing the risk of adverse effects associated with peaks and troughs in drug concentration.

Example: Propranolol SR and diltiazem SR are used to manage hypertension and angina effectively. [13]

- **Psychiatric Disorders**

Medications for psychiatric conditions often rely on sustained-release formulations to enhance adherence and minimize side effects caused by fluctuating drug levels. They provide consistent therapeutic effects throughout the day.

Example: Bupropion SR is used for depression and smoking cessation.

- **Gastrointestinal Disorders**

Sustained-release systems are applied in the treatment of gastrointestinal conditions where prolonged drug action is beneficial, such as peptic ulcers and inflammatory bowel diseases.

Example: Mesalamine SR tablets are used for ulcerative colitis, ensuring targeted release in the colon.

- **Hormone Therapy**

SR formulations are employed in hormone replacement therapies or contraceptive systems to deliver a steady release of hormones over an extended duration.

Example: Progesterone SR tablets or implants are used in contraception and hormone replacement therapy.

- **Antibiotic Therapy**

Sustained-release antibiotics are designed to maintain therapeutic levels for longer periods, reducing dosing frequency and improving patient compliance.

Example: Azithromycin SR is used for treating bacterial infections with single-dose therapy**.** [14]

- **Neurological Disorders**

SR systems are utilized in the treatment of neurological disorders such as Parkinson's disease and epilepsy to ensure stable drug delivery and reduce symptom fluctuations.

Example: Levodopa-carbidopa SR tablets are used to provide consistent symptom control in Parkinson's disease.

- **Anti-Cancer Therapy**

In oncology, sustained-release formulations are designed to provide controlled drug delivery, minimizing side effects while maintaining therapeutic efficacy.

Example: Temozolomide SR capsules are being explored to enhance treatment outcomes in glioblastoma. [15]

- **Localized Drug Delivery**

SR systems are used for localized drug delivery in areas like the eye (ocular inserts), oral cavity (mucoadhesive tablets), and rectum (suppositories) to prolong the drug's action at the site of application.

Example: Pilocarpine SR inserts are used for glaucoma to maintain intraocular pressure control.

- **Vaccination**

SR systems are being explored for use in vaccine delivery, where they provide prolonged immune stimulation with a single dose, improving convenience and compliance.

Example: Microparticle-based SR systems for vaccines in development. [16]

- **Anti-inflammatory Therapy**

Drugs for inflammatory conditions like arthritis are formulated in sustained-release systems to provide long-lasting relief and minimize gastrointestinal side effects.

Example: Diclofenac SR tablets are used for managing chronic inflammatory conditions.

Conclusion

Sustained release tablets represent a cornerstone in modern pharmaceutical development, offering numerous advantages over conventional formulations. By employing advanced materials and rigorous evaluation techniques, SR tablets enhance therapeutic outcomes, improve patient compliance, and reduce side effects. However, addressing formulation challenges is essential to maximize their potential. As technology evolves, sustained release systems will continue to play a pivotal role in advancing personalized medicine and improving healthcare outcomes. [17]

References

1. Zalte HD, Saudagar RB. Review on sustained release matrix tablet. International journal of pharmacy and biological sciences. 2013;3(4):17-29.
2. Manish J, Abhay K. Sustained Release Matrix Type Drug Delivery System: A Review. J. Drug Deliv. Ther. 2012;2(6):142–8.
3. Zalte H, Saudagar R. Review on Sustained Release Matrix Tablet. Int. J. Pharm. Biol. Sci. 2013;3(4):17–29.
4. Shah N, Oza C, Trivedi S, Shah N, Shah S. Review on sustained release matrix tablets: An approach to prolong the release of drug. J Pharm Sci Bio Sci Res. 2015;5(3):315-21.
5. Bose, S., Kaur, A., & Sharma, S. K. A Review on Sustained release drug delivery system. International Research Journal of Pharmacy, 2013;149–515.
6. Patel, C. J., & Satyanand, T, Novel sustained release drug delivery: A modern review. International Journal of Applied Pharmaceutics, 2014;1:115–119.
7. Parashar T, Soniya SV, Singh G, Tyagi S, Patel C, Gupta A. Novel oral sustained release technology: a concise review. Int J Res Dev Pharm Life Sci. 2013;2(2):262-9.
8. Gourlay GK. Sustained relief of chronic pain: pharmacokinetics of sustained release morphine. Clinical pharmacokinetics. 1998; 35:173-90.
9. Isha C, Nimrata S, Rana AC, Surbhi G. Oral sustained release drug delivery system: an overview. The International Research Journal of Pharmacy. 2012;3(5):43-8.
10. Pachori A, Joshi A, Kumar K, Ikram I, Rajput V. A comprehensive review on sustained release tablets. Journal of Integral Sciences. 2023; 8-12.
11. Ahmed V, Sharma S, Bhatt P. Formulation and evaluation of sustained release tablet of diltiazem

hydrochloride. International Journal of Pharmaceutical Sciences and Research. 2020;11(5):2193-8.

12. Samie M, Bashir S, Abbas J, Samiullah KH, Nargis AM, Habibullah JA, Muhammad N. Design, formulation and in vitro evaluation of sustained-release tablet formulations of levosulpiride. Turkish Journal of Pharmaceutical Sciences. 2018; 15(3):309.
13. Patil HG, Tiwari RV, Repka MA, Singh KK. Formulation and development of orodispersible sustained release tablet of domperidone. Drug development and industrial pharmacy. 2016;42(6):906-15.
14. Shergill M, Patel M, Khan S, Bashir A, McConville C. Development and characterisation of sustained release solid dispersion oral tablets containing the poorly water-soluble drug disulfiram. International journal of pharmaceutics. 2016 ;497(1-2):3-11.
15. Lamoudi L, Chaumeil JC, Daoud K. Development of gastro intestinal sustained release tablet formulation containing acryl-EZE and pH-dependent swelling HPMC K 15 M. Drug Development and Industrial Pharmacy. 201;38(5):515-20.
16. Ford, J.L.; Rubinstein, M.H.; Hogan, J.E. Formulation of sustained release promethazine hydrochloride tablets using hydroxypropyl-methylcellulose matrices. Int. J. Pharm. 1985, 24, 327–338.
17. Wang L, Liu X. Sustained release technology and its application in environmental remediation: a review. International Journal of Environmental Research and Public Health. 2019;16(12):2153.